The following are resources that you may find helpful as you navigate your squamous cell skin cancer journey.
AIM at Melanoma Foundation
AIM at Melanoma (AIM) is a global foundation dedicated to finding more effective treatments and, ultimately, the cure for melanoma, while improving the lives of those it affects. AIM directs and funds paradigm-shifting research initiatives; educates patients, healthcare professionals, and the public; and advocates for survivors and their families, with the goal of ending this disease in our lifetime.
American Cancer Society
The mission of American Cancer Society (ACS) is to save lives, celebrate lives, and lead the fight for a world without cancer.
American Academy of Dermatology
The American Academy of Dermatology (AAD) is a professional society of physicians who specialize in the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails. It advocates for high standards in clinical practice, education, and research in dermatology and promotes quality patient care through its 20,000-plus member physicians.
For more than 75 years, CancerCare has focused on helping patients with advanced cancer receive emotional support and assistance with practical needs. Its network of social workers offers free psychosocial support services, hosts nearly 200 support groups, provides financial assistance, conducts educational workshops, and issues publications on cancer-related issues. Its Online Helping Hand is a comprehensive database of national and regional organizations that deal with the impact of advanced cancer.
Cancer Support Community
The Cancer Support Community (CSC) is dedicated to ensuring that all who are impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community. Affiliated with the CSC global network of cancer support are the Gilda’s Club centers and various healthcare partnerships. CSC also maintains a toll-free helpline and advocates at all levels of government for those dealing with a cancer diagnosis.
A website affiliated with the American Society of Clinical Oncology (ASCO), a professional organization of cancer physicians and oncology professionals, Cancer.net provides trusted, compassionate information for people with cancer and their families and caregivers. Featured on the site are aids to finding a cancer doctor, information on types of cancer, patient education materials, the latest treatment options, and advice on caring for a cancer patient.
Look Good Feel Better
Look Good Feel Better is a nonmedical, brand-neutral public service program for women diagnosed with cancer. The Look Good Feel Better program is made possible through a collaboration of the Look Good Feel Better Foundation (the charitable arm of the trade group representing the cosmetics and beauty industry) and the Professional Beauty Association, the largest organization of salon professionals with members representing salons/spas, distributors, manufacturers, and beauty professionals. It conducts group workshops as well as virtual workshops online for those unable to attend group settings.
NCCN Guidelines for Patients® Squamous Cell Skin Cancer. 2019.
Available at https://www.nccn.org/patients/guidelines/content/PDF/squamous_cell-patient.pdf
The National Comprehensive Cancer Network, through its Foundation, has produced a thorough sourcebook that encompasses the latest information on the disease, treatment options, and post-treatment advice. The many Illustrations and graphics help clarify the text, which is written for the lay audience.
Save Your Skin Foundation
Save Your Skin Foundation (SYS) is dedicated to providing support to all Canadians who are living with skin cancer. The foundation offers both financial assistance and emotional support to patients, promotes education and awareness of skin cancer to the general public, and advocates for research on behalf of skin cancer patients throughout Canada.
UNOS Transplant Living
UNOS Transplant Living is the patient resource site of United Network for Organ Sharing, the private non-profit organization that manages the US organ transplantation system under contract with the federal government. It provides a range of support services for patients before and after transplantation, including support groups.
XP Family Support Group
The Xeroderma Pigmentosum (XP) Family Support Group exists to improve the quality of life for people with XP and other diagnosed UV light conditions. The Xeroderma Pigmentosum Family Support Group strives to create awareness and educate the public about XP, as well as to raise funds to promote research, create collaborations with international XP partner organizations, and provide family grants for UV protective equipment and travel assistance for attending the annual XP national convention.
The Merck Access Program
855-257-3932 (or 855-257-7332 for the hearing impaired)
REGENERON SANOFI-GENZYME RESOURCES
Libtayo Surround Program 1-877-542-8296
https://www.libtayo.com/nsclc/libtayo-surround (lung-cancer specific; support for other disease states can be found by selecting another cancer type)
Other Financial Resources
FAMILY AND MEDICAL LEAVE ACT
Entitles eligible employees of covered employers to take unpaid, job-protected leave for specified family and medical reasons with continuation of group health insurance coverage under the same terms and conditions as if the employee had not taken leave. https://www.dol.gov/agencies/whd/fmla
GROWING FAMILY BENEFITS
This organization provides guidance on getting cancer treatment without health insurance.
This organization helps federally and commercially insured people living with life threatening, chronic and rare diseases with the out-of-pocket costs for their prescribed medications.
Alam M, Nanda S, Mittal BB, Kim NA, Yoo S. The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. J Am Acad Dermatol. 2011;65:377-388.
American Academy of Dermatology. Skin cancer: squamous cell carcinoma treatment. https://www.aad.org/public/diseases/skin-cancer/types/common/scc/treatment. Accessed March 2, 2020.
American Cancer Society. Cancer Facts and Figures 2020. Atlanta, GA: American Cancer Society; 2020.
Bonanno A, Esmaeli B, Fingeret MC, Nelson DV, Weber RS. Social challenges of cancer patients with orbitofacial disfigurement. Ophthalmic Plast Reconstr Surg. 2010; 26:18-22.
Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23:759-765.
Fisher J, Zeitouni N, Fan W, Faramarz SH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systemic review. J Am Acad Dermatol. 2020;82:1490-1500.
Gold KA, Kies MS, William WN Jr, Johnson FM, Lee JJ, Glisson BS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single arm phase II clinical trial. Cancer. 2018;124:2169-2173.
Grob JJ, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol. 2020; 38:2916-2925.
Kang SY, Toland AE. High risk cutaneous squamous cell carcinoma of the head and neck. World J Otorhinolaryngol Head Neck Surg. 2016;2:136-140.
Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68:957-966.
Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014;32:327-334.
Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. In: Reichrath J, ed. Sunlight, Vitamin D and Skin Cancer. 2nd ed. Austin, TX: Landes Bioscience and Springer Science+Business Media; 2014:120-140.
Marrazzo G, Zitelli JA, Brodland D. Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone. J Am Acad Dermatol. 2019;80:633-638.
Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341-351.
Muzic JG, Schmitt AR, Wright AC, et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: a population-based study in Olmsted County, Minnesota, 2000 to 2010. Mayo Clin Proc. 2017;92:890-898.
National Cancer Institute. Skin Cancer Treatment (PDQ®)—Health Professional Version. https://www.cancer.gov/types/skin/hp/skin-treatment-pdq#_331. Updated December 17, 2019.
National Comprehensive Cancer Network. NCCN Guidelines for Patients®. NCCN Quick Guide™: Squamous cell skin cancer. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2019. https://www.nccn.org/patients/guidelines/content/PDF/nccnquickguide-squamouscell-patient.pdf. Accessed February 27, 2020.
National Comprehensive Cancer Network. NCCN Guidelines for Patients®. Squamous Cell Skin Cancer. Plymouth Meeting, PA: National Comprehensive Cancer Network® (NCCN®) and NCCN Foundation®; 2019.
Palyca P, Koshenkov VP, Mehnert JM. Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need. Am Soc Clin Oncol Educ Book. 2014:e397-e404.
Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78:237-247.
Răducu L, Avino A, Purnichescu Purtan R, Balcangiu-Stroescu A-E, et al. Quality of life in patients with surgically removed skin tumors. Medicina. 2020; 56:E66.
Regeneron Pharmaceuticals. Libtayo prescribing information. Tarrytown, NY: Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC; 2019.
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151:1081-1086.
Roscher I, Falk RS, Vos L, et al. Validating 4 staging systems for cutaneous squamous cell carcinoma using population-based data: a nested case-control study. JAMA Dermatol. 2018;154:428-434.
Ruiz ES, Karia PS, Besaw R, Schmults CD. Performance of the American Joint Committee on Cancer Staging Manual, 8th edition vs the Brigham and Women’s Hospital tumor classification system for cutaneous squamous cell carcinoma. JAMA Dermatol. 2019;155:819-825.
Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149:541-547.
Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-ebased model. Arch Dermatol. 2010;146:279-282.
U.S. Department of Health and Human Services. The Surgeon General’s Call to Action to Prevent Skin Cancer. Washington, DC: U.S. Department of Health and Human Services, Office of the Surgeon General; 2014.
Work Group; Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018a;78:560-578.
Work Group; Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018b;78:540-559.